NCT00870311View on ClinicalTrials.gov

Investigation of Lithium on Signal Transduction, Gene Expression and Brain Myo-Inositol Levels in Manic Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

March 31, 1996

Primary Completion Date

April 30, 2004

Study Completion Date

April 30, 2004

Conditions
Bipolar Disorder
Interventions
DRUG

Lithium Carbonate

300mg PO, three times daily with dose titrated to obtain a therapeutic plasma level of 0.8 to 1.2meq/L) over the first week of treatment. Total duration is a minimum of 3 weeks. Medication is dispensed in the form of blinded research capsules.

Trial Locations (1)

48201

Wayne State University School of Medicine, Detroit

All Listed Sponsors
collaborator

National Institute of Mental Health (NIMH)

NIH

lead

Wayne State University

OTHER

NCT00870311 - Investigation of Lithium on Signal Transduction, Gene Expression and Brain Myo-Inositol Levels in Manic Patients | Biotech Hunter | Biotech Hunter